Soligenix anounces publication showing efficacy of ebolavirus and MARV vaccine

Soligenix announced a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus – SUDV – and Marburg marburgvirus – MARV – infections. The manuscript has been published in Vaccine. This vaccine candidate has been previously demonstrated to be stable to high temperature storage for at least 2 years at 40 degrees Celsius. There are currently no approved vaccines or therapeutics for either SUDV or MARV infections. The published paper describes the potency of the bivalent formulation against both viruses, demonstrating 100% protection in the most rigorous non-human primate challenge models. The thermostabilized filovirus vaccine program is continuing to advance with the support of a National Institute of Health grant awarded to UHM and a Small Business Innovation Research grant awarded to Soligenix.